AITRICS secures Indonesian regulatory approval for AI patient deterioration prediction solution

South Korean medical artificial intelligence company AITRICS has received medical device approval from Indonesia’s Ministry of Health for its patient deterioration prediction solution, AITRICS-VC (VitalCare), marking the product’s fifth regulatory clearance globally.

The approval positions AITRICS to capitalise on Indonesia’s accelerating digital health agenda as the government pushes forward with its 2025–2029 Digital Health Transformation Strategy (DHTS), which prioritises the development of smart hospitals and the adoption of AI-based standalone Software as a Medical Device (SaMD) within the SATUSEHAT national health data platform.

AITRICS-VC (VitalCare) draws on electronic medical record (EMR) data to identify patients at elevated risk of deterioration before critical events occur. In general ward settings, the solution monitors for major adverse events including death, ICU transfer, cardiac arrest, and sepsis. In intensive care units, it focuses on mortality risk prediction, enabling clinical teams to prioritise and respond to high-risk patients more rapidly.

With the Indonesian approval now in place, AITRICS-VC (VitalCare) has obtained regulatory clearance across five markets: South Korea, the United States, Vietnam, Hong Kong, and Indonesia. The company says it intends to build on this foundation, with approval procedures currently advancing in Singapore and Malaysia.

Indonesia’s digital health transformation reaches 270 million patients as AI governance framework takes shape

As Southeast Asia’s most populous nation, Indonesia represents a substantial opportunity for medical technology providers. The government’s SATUSEHAT platform is designed to establish data connectivity and interoperability across the country’s healthcare institutions, creating the foundational infrastructure needed for broader AI adoption at scale.

The regulatory and policy environment developing around SATUSEHAT is broadly supportive of solutions in the patient monitoring and clinical decision support space. AITRICS says it expects the Indonesian approval to serve as a springboard for wider regional expansion, with post-market obligations in Indonesia running in parallel with further market entry activity across Southeast Asia.